MedTrace Logo

Arginase Inhibition and Microvascular Endothelial Function in Type 2 Diabetes

NCT02687152 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2016-02-22

No results posted yet for this study

Summary

The present project is designed to test the hypothesis that arginase contributes to microvascular endothelial dysfunction in patients with type 2 diabetes and microvascular complications.

Conditions

Interventions

OTHER

N-hydroxy-nor-L-arginine

Sponsors & Collaborators

Principal Investigators

  • John Pernow, MD, PhD · Karolinska Institutet

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-11-30
Completion
2016-01-31

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02687152 on ClinicalTrials.gov